SET-171

SET-171 is a JNK (c-Jun N-terminal kinase) inhibitor that exhibits significant anticancer activity and lipid metabolism regulation by inhibiting liver pyruvate kinase (PKL) expression. In anticancer studies, SET-171 shows IC50 values of 8.82 μM and 2.97 μM against HepG2 and Huh7 cell lines, respectively, indicating high cytotoxicity. Additionally, in non-alcoholic fatty liver disease (NAFLD) -related studies, SET-171 significantly reduces triacylglycerol (TAG) levels and inhibits the expression of steatosis-related proteins. SET-171 holds promise for research on hepatocellular carcinoma (HCC) and NAFLD[1].

Product Specifications

CAS Number

[3052985-32-4]

UNSPSC

12352005

Target

JNK; Pyruvate Kinase

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; Metabolic Enzyme/Protease

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/set-171.html

Smiles

BrC1=CC=CC(NC(CN2CCC3=C(SC(NC(C4=CC=CC5=C4C=CC=C5)=O)=C3C#N)C2)=O)=C1

Molecular Formula

C27H21BrN4O2S

Molecular Weight

545.45

References & Citations

[1]Iqbal S, et al. Design and synthesis of novel JNK inhibitors targeting liver pyruvate kinase for the treatment of non-alcoholic fatty liver disease and hepatocellular carcinoma. Bioorg Chem. 2024 Jun;147:107425.